Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory
multiple myeloma (MM) have been poor because of a dearth of effective treatment options …

Immunomodulatory imide drugs (IMiDs), proteasome inhibitors (PIs) and anti‐CD38
monoclonal antibodies (MoAbs) are the pillars of modern multiple myeloma (MM) therapy …

CCS1477 (inobrodib) is a potent, selective EP300/CBP bromodomain inhibitor which
induces cell-cycle arrest and differentiation in hematologic malignancy model systems. In …

Objectives Among advanced multiple myeloma (MM) patients, B-cell maturation antigen
(BCMA) specific targets like Belantamab Mafodotin (belamaf) and CAR T-cell therapies have …

The treatment of multiple myeloma has evolved significantly over the past few decades with
the development of novel therapeutics. The introduction of proteasome inhibitors …

Introduction For patients with triple-class exposed/refractory multiple myeloma (TCE/R MM),
prognosis is poor and effective treatment options are limited. Elranatamab is a novel B-cell …

There is a lack of consensus on therapy sequencing in previously treated multiple myeloma,
particularly after anti‐B‐cell maturation antigen (BCMA) therapy. Earlier reports on selinexor …

Clinical trial eligibility and regulatory approvals of new treatments often define populations of
patients with relapsed, refractory multiple myeloma (RRMM) based on the number of prior …

For patients with triple-class exposed/refractory multiple myeloma (TCE/RMM), where
effective treatments options are limited, B-cell maturation antigen and CD3-directed …

The success of chimeric antigen receptor T‐cell (CAR‐T) therapy in hematologic
malignancies has realized a longstanding effort toward harnessing the immune system to …